ArticleInternational journal of genomics2026
Ubiquitin-Proteasome System-Related Prognostic Model and Immune Landscape in Glioblastoma.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ubiquitin-Proteasome System-Related Prognostic Model and Immune Landscape in Glioblastoma.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma (GBM) is a highly aggressive brain tumor with poor prognosis. This study is aimed at establishing an ubiquitin-proteasome system (UPS)-related prognostic model and investigating its link to immune infiltration and therapy response. Materials and Methods: GBM datasets were obtained from public databases. Ubiquitin-proteasome system-related genes (UPSGs) were identified from literature. Consensus clustering defined UPS-based GBM subtypes. Differentially expressed genes (DEGs) were screened, and a prognostic model was constructed using univariate Cox, least absolute shrinkage and selection operator (LASSO), and stepwise regression. The model's performance was validated using survival analysis and time-dependent receiver operating characteristic (ROC) curves. Immune infiltration was assessed using single-sample gene set enrichment analysis (ssGSEA), TIMER, and ESTIMATE. Drug sensitivity was assessed by correlating the half-maximal inhibitory concentration (IC Results: Two UPS-related GBM subtypes were identified. Six genes ( Conclusion: This study establishes a UPS-based prognostic model for GBM that links immune infiltration and drug sensitivity, providing potential biomarkers and therapeutic targets for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.